Trial Profile
Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study During PCV National Vaccination Programme [SUBSTUDY OF 700042614]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
- Indications Pneumococcal infections; Pneumonia
- Focus Pharmacodynamics
- Acronyms FinIP-carriage
- 12 Jul 2017 Primary endpoint (Carriage due to any pneumococcal serotype included in the ten-valent pneumococcal conjugate vaccine (PCV10) in children vaccinated in infancy) has been met, according to the results published in the Pediatric Infectious Disease Journal
- 12 Jul 2017 Results assessing Direct and Indirect Effectiveness of the Ten-Valent Pneumococcal Conjugate Vaccine Against Carriage in three FinIP trials (FinIP, FinIPcarr and FinIP-carriage) published in the Pediatric Infectious Disease Journal
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.